SOMERVILLE, Mass., June 02, 2025--bluebird bio (NASDAQ: BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by ...

Carlyle and SK Capital have provided significant primary capital to support and scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

After a sluggish start to 2025, the primary market is showing signs of revival with over a dozen companies having lined up ...

Indian primary market shows signs of revival with over a dozen IPOs lined up for the next six months. HDB Financial Services, ...

The nearly $6 billion BlueOval SK battery park is hard to miss from Interstate 65, just past the Glendale exit in Hardin ...

Mumbai: After a quiet start to 2025, India’s primary market is finally showing signs of recovery. Over 12 companies are ...

Sandisk has emerged from its spin-off with financial stability but now faces the challenge of proving its independence. Check ...

GRC, a provider of single-phase immersion cooling for data centers, has secured investment from Samsung. The company this ...

Hedge funds revealed their top investment ideas, from Chinese self-driving taxis to an Indian drug retailer, at the annual ...

Expansion underscores South Korea’s strategic AI leadership and surging demand for ChatGPT Since the start of 2024, South ...

After a sluggish start to 2025, the primary market is showing signs of revival with over a dozen companies having lined up ...